Literature DB >> 27155599

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

B F Hoyer1, F Hiepe2.   

Abstract

Immunomodulatory therapy is the gold standard in the treatment of autoimmune diseases. Increasing knowledge of the underlying mechanisms leading to autoimmunity enables patients to be treated with better and more specific therapies apart from the classical therapies, such as antimalarial drugs and glucocorticoids. For patients this nowadays means a great chance to receive optimized therapy. Numerous treatment options have been developed over the last decades and the development of new treatment approaches and strategies is still ongoing. This review gives an overview of immunomodulatory therapy approaches.

Entities:  

Keywords:  Biologics; Immunomodulation; Immunosuppression; MicroRNA; Remission

Mesh:

Substances:

Year:  2016        PMID: 27155599     DOI: 10.1007/s00347-016-0263-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  35 in total

1.  Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?

Authors:  Christoph Tappeiner; Carsten Heinz; Gerd Ganser; Arnd Heiligenhaus
Journal:  J Rheumatol       Date:  2012-06       Impact factor: 4.666

Review 2.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Changes in circulating leukocytes induced by the administration of pituitary adrenocorticotrophic hormone in man.

Authors:  A G HILLS; P H FORSHAM; C A FINCH
Journal:  Blood       Date:  1948-07       Impact factor: 22.113

4.  INFLUENCE OF ADRENAL CORTICAL SECRETION ON BLOOD ELEMENTS.

Authors:  T F Dougherty; A White
Journal:  Science       Date:  1943-10-22       Impact factor: 47.728

5.  [Adrenocortical preparations in psoriasis].

Authors:  T GRUNEBERG
Journal:  Dermatol Wochenschr       Date:  1951

Review 6.  Behçet's disease: an algorithmic approach to its treatment.

Authors:  Erkan Alpsoy; Ayse Akman
Journal:  Arch Dermatol Res       Date:  2009-08-21       Impact factor: 3.017

7.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors:  K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

Review 8.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

9.  Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis.

Authors:  R O Graham; G A Peyman
Journal:  Arch Ophthalmol       Date:  1974-08

10.  Azathioprine for glucocorticoid resistant noninfectious uveitis.

Authors:  Ilhem Mili-Boussen; Monia Zitouni; Imen Ammous; Imene Letaief; Khalil Errais; Raja Zhioua; Narjesse Khalfallah
Journal:  Tunis Med       Date:  2015-03
View more
  2 in total

1.  [Optimization of therapy of autoimmune diseases of the eye : Novel approaches].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

2.  Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity.

Authors:  Yan Wang; Lily Guo; Xihui Yin; Ethan C McCarthy; Mandy I Cheng; Aline T Hoang; Ho-Chung Chen; Anushi Y Patel; Denise Allard Trout; Erin Xu; Natalie Yakobian; Willy Hugo; James F Howard; Katherine M Sheu; Alexander Hoffmann; Melissa G Lechner; Maureen A Su
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.